Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

Autor:	Yap TA; Drug Development Unit, Royal Marsden Hospital, London, England, United Kingdom., Winter JN; Medicine (Hematology and Oncology), Robert H. Lurie Comprehensive Cancer Center and Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Giulino-Roth L; Departments of Pediatrics and Medicine and Laboratory Medicine, Weill Cornell Medical College, New York, New York., Longley J; Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom., Lopez J; Consultant Medical Oncologist, Institute of Cancer Research, Royal Marsden, London, United Kingdom., Michot JM; Department of Hematology and Innovative Drugs, Institut Gustave Roussy, France., Leonard JP; Departments of Pediatrics and Medicine and Laboratory Medicine, Weill Cornell Medical College, New York, New York., Ribrag V; Department of Hematology and Innovative Drugs, Institut Gustave Roussy, France., McCabe MT; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Creasy CL; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Stern M; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Pene Dumitrescu T; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Wang X; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Frey S; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Carver J; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Horner T; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Oh C; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Khaled A; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Dhar A; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Johnson PWM; Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom. johnsonp@soton.ac.uk.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Dec 15; Vol. 25 (24), pp. 7331-7339. Date of Electronic Publication: 2019 Aug 30.
DOI:	10.1158/1078-0432.CCR-18-4121
Abstrakt:	Purpose: Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. Patients and Methods: This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (NCT02082977). Doses of GSK2816126 ranged from 50 to 3,000 mg twice weekly, and GSK2816126 was given 3-weeks-on/1-week-off in 28-day cycles. Eligible patients had solid tumors or B-cell lymphomas with no available standard treatment regimen. Results: Forty-one patients (21 solid tumors, 20 lymphoma) received treatment. All patients experienced ≥1 adverse event (AE). Fatigue [22 of 41 (53.7%)] and nausea [20 of 41 (48.8%)] were the most common toxicity. Twelve (32%) patients experienced a serious AE. Dose-limiting elevated liver transaminases occurred in 2 of 7 patients receiving 3,000 mg of GSK2816126; 2,400 mg was therefore established as the MTD. Following intravenous administration of 50 to 3,000 mg twice weekly, plasma GSK2816126 levels decreased biexponentially, with a mean terminal elimination half-life of approximately 27 hours. GSK2816126 exposure (maximum observed plasma concentration and area under the plasma-time curve) increased in a dose-proportional manner. No change from baseline in H3K27me3 was seen in peripheral blood mononuclear cells. Fourteen of 41 (34%) patients had radiological best response of stable disease, 1 patient with lymphoma achieved a partial response, 21 of 41 (51%) patients had progressive disease, and 5 patients were unevaluable for antitumor response. Conclusions: The MTD of GSK2816126 was established at 2,400 mg, but the dosing method and relatively short half-life limited effective exposure, and modest anticancer activity was observed at tolerable doses. (©2019 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu